Cara Therapeutics Company Profile (NASDAQ:CARA)

Cara Therapeutics trades on the NASDAQ under the ticker symbol "CARA."

Cara Therapeutics, Inc. (NASDAQ:CARA) issued its earnings results on Thursday, August, 3rd. The company reported ($0.29) EPS for the quarter, beating analysts' consensus estimates of ($0.61) by $0.32. Cara Therapeutics's quarterly revenue was down 100.0% on a year-over-year basis. During the same period last year, the business earned ($0.48) earnings per share. View Cara Therapeutics' Earnings History.

11 brokers have issued 12 month price objectives for Cara Therapeutics' shares. Their forecasts range from $20.00 to $32.00. On average, they anticipate Cara Therapeutics' stock price to reach $26.67 in the next year. View Analyst Ratings for Cara Therapeutics.

Here are some recent quotes from research analysts about Cara Therapeutics stock:

• 1. According to Zacks Investment Research, "Cara Therapeutics, Inc. is a biopharmaceutical company. The company is focused on developing and commercializing new chemical entities designed to alleviate pain. Cara Therapeutics, Inc. is based in Shelton, United States. " (8/30/2017)
• 2. Needham & Company LLC analysts commented, "Cara announced outcome of planned CR845 Phase 2/3 post-surgical pain trial interim power assessment today. We spoke w/ mgmt for an update. No changes will be made to current randomization ratio across the 3 arms (1:1:1 placebo, 0.5 ug/kg, 1.0ug/kg), however target enrollment will be increased from 125/ arm to 150/ arm. Other pre-specified options were ending trial early due to low probability of success or shifting enrollment to one optimal dose. We view outcome favorably, noting that the two dose arms were evaluated independently by Data Monitoring Cmtee. Implication is that both low and high dose CR845 have potential for statistically significant effect in view of DMC. We had been concerned that low and possibly high dose evaluated in this trial may not be sufficiently high for efficacy. Mgmt guided for completing enrollment for final analysis by YE17. Separately, top-line results from CR845 Phase 2b trial in Osteoarthritis are expected later this month. We are favorably inclined based on encouraging trends in an 80-pt 2wk Phase 2a trial, but acknowledge risks tied to absence of placebo arm." (6/21/2017)
• 3. HC Wainwright analysts commented, "CR845 as safe as placebo in respiratory safety Phase 1. Cara announced positive data this morning from a 15-patient Phase 1 trial in healthy volunteers designed to formally test for IV ‘845’s impact on respiratory drive, as respiratory depression remains one of the more severe, and potentially life-threatening, side effects of mu opioids, which ‘845 is not. The trial was a three-way crossover design utilizing the expected therapeutic dose of 1.0 ug/kg, as well as a 5.0 ug/kg supratherapeutic dose to test the upper bounds for safety. Patient respiratory drive was measured via end-tidal CO2 (ETCO2), oxygen saturation (SpO2), and respiratory rate, with primary endpoints focused on the former two. ETCO2 ranged from 36.1 to 37.8 mmHg prior to dosing, and remained well below the endpoint threshold of a 10mmHg sustained increase in ETCO2, with values of 38.1, 38.1, and 38.3 mmHg for the placebo, 1.0 ug/kg, and 5.0 ug/kg doses, respectively, one hour after administration. Both doses of ‘845 also hit on the SpO2 primary endpoint (needed to show SpO2 which did not consistently fall below 92%), with pre-treatment levels ranging from 98.3% to 98.9%, finishing an hour later at 97.8%, 98.2%, and 97.9% for the placebo,1.0 ug/kg, and 5.0 ug/kg doses, respectively. While these two primary endpoints only measured through an hour after treatment, no significant differences were seen on all three measures of respiratory drive throughout the entire 4-hour observation period of the study." (4/24/2017)
• 4. Cantor Fitzgerald analysts commented, "The Phase 1 safety trial of IV CR845 showed no significant differences in respiratory drive vs. placebo at super-therapeutic dosing levels." (4/24/2017)
• 5. Piper Jaffray Companies analysts commented, "Today Cara reported positive results from Part A of its Phase II/III trial for IV CR845 in uremic pruritus (UP). In our view, these results are compelling in terms of impact on worst itching scores together with more global measures of quality of life within the context of an 8-week study, as well as safety/tolerability at the go-forward doses of 0.5mcg/kg and 1.0mcg/kg. We see the robust efficacy vs safety data from this Phase II as reducing clinical risk for a broader pivotal program planned to begin by YE17. And beyond the Phase III program, we see this dataset as potentially reducing regulatory and commercial risk, and enhancing value of this asset, in the longer-term. In advance of further clinical progress in UP, including an EOP2 and Phase III start yet in '17, as well as chronic pain and post-op pain updates during 2Q17, we reiterate OW on Cara." (3/28/2017)

Some companies that are related to Cara Therapeutics include Heron Therapeutics (HRTX), Enanta Pharmaceuticals (ENTA), Crispr Theraptc (CRSP), TG Therapeutics (TGTX), Spectrum Pharmaceuticals (SPPI), WAVE Life Sciences (WVE), Abeona Therapeutics (ABEO), ImmunoGen (IMGN), AC Immune SA (ACIU), ANI Pharmaceuticals (ANIP), Inovio Pharmaceuticals (INO), Celyad SA (CYAD), Kala Pharmaceuticals (KALA), PDL BioPharma (PDLI), Adamas Pharmaceuticals (ADMS), Voyager Therapeutics (VYGR), Mesoblast Limited (MESO) and Agenus (AGEN).

Cara Therapeutics' management team includes the folowing people:

• Derek T. Chalmers Ph.D., President, Chief Executive Officer, Director
• Josef C. Schoell CPA, Chief Financial Officer
• Frederique Menzaghi Ph.D, Vice President, Research & Development
• Joseph William Stauffer, Chief Medical Officer
• Harrison M. Bains Jr., Independent Director
• Jeffrey L. Ives Ph.D., Independent Director
• Dean Slagel, Independent Director
• Martin A. Vogelbaum, Independent Director

Cara Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include RHO Capital Partners Inc. (10.98%), State Street Corp (9.96%), FMR LLC (3.69%), Vanguard Group Inc. (3.41%), Disciplined Growth Investors Inc. MN (2.69%) and Balyasny Asset Management LLC (1.61%). Company insiders that own Cara Therapeutics stock include Dean Slagel, Derek T Chalmers, Frederique PhD Menzaghi, Michael E Lewis and Ventures Vi Lp Rho. View Institutional Ownership Trends for Cara Therapeutics.

Cara Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Franklin Resources Inc., UBS Asset Management Americas Inc., C WorldWide Group Holding A S, Tiverton Asset Management LLC, National Planning Corp, Russell Investments Group Ltd., Parametric Portfolio Associates LLC and EAM Investors LLC. Company insiders that have sold Cara Therapeutics stock in the last year include Dean Slagel, Derek T Chalmers and Frederique PhD Menzaghi. View Insider Buying and Selling for Cara Therapeutics.

Cara Therapeutics' stock was bought by a variety of institutional investors in the last quarter, including State Street Corp, Balyasny Asset Management LLC, FMR LLC, Vanguard Group Inc., Quantitative Investment Management LLC, Nomura Holdings Inc., Northern Trust Corp and Swiss National Bank. View Insider Buying and Selling for Cara Therapeutics.

Shares of Cara Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Cara Therapeutics stock can currently be purchased for approximately $13.06.